Foundation Focus | July 2025
July 29, 2025
Listen to podcast
Bold Conversations: Misinformation with Dr. Cynthia Baur
July 23, 2025
Listen to podcast
ChronicXTwenties: Demystifying advocacy
July 17, 2025
Listen to podcast
Takhzyro
Plasma kallikrein inhibitor (monoclonal antibody)
Approved to prevent attacks of Hereditary Angioedema (HAE) in adult and pediatric patients 2 years and older.
Report side effects/adverse events at 1-800-FDA-1088.
Orladeyo
Plasma kallikrein inhibitor
Approved to prevent attacks of Hereditary Angioedema (HAE) in adults and pediatric patients 12 years and older.
Report side effects/adverse events at 1-800-FDA-1088.
Kalbitor
Plasma kallikrein inhibitor
Approved to treat acute attacks of Hereditary Angioedema (HAE) in patients 12 years and older.
Report side effects/adverse events at 1-800-FDA-1088.
Firazyr
Bradykinin B2 receptor antagonist
Approved to treat acute attacks of Hereditary Angioedema (HAE) in adults 18 years and older.
Report side effects/adverse events at 1-800-FDA-1088.
Andembry
Activated Factor XII (FXIIa) inhibitor (monoclonal antibody)
Approved to prevent attacks of Hereditary Angioedema (HAE) in adult and pediatric patients aged 12 years and older.
Report side effects/adverse events at 1-866-915-6958.
Berinert
C1 Esterase Inhibitor (Human)
Approved to treat acute abdominal or facial or laryngeal attacks of Hereditary Angioedema (HAE) in adult and adolescent patients.
Report side effects/adverse events at 1-866-915-6958.
